Assenagon Asset Management S.A. Sells 146,879 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Assenagon Asset Management S.A. decreased its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 14.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 905,184 shares of the company’s stock after selling 146,879 shares during the period. Assenagon Asset Management S.A. owned 1.16% of Kura Oncology worth $7,884,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. grew its holdings in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after buying an additional 3,092 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after buying an additional 302,000 shares during the period. HighVista Strategies LLC bought a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $345,000. Finally, Alethea Capital Management LLC boosted its holdings in Kura Oncology by 2.4% during the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after acquiring an additional 6,300 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KURA. UBS Group started coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Scotiabank reduced their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Bank of America lowered their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Finally, Jefferies Financial Group reduced their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Price Performance

Shares of KURA stock opened at $7.26 on Monday. The company has a market cap of $564.54 million, a P/E ratio of -3.08 and a beta of 0.81. The stock’s 50-day moving average is $10.51 and its 200 day moving average is $16.33. Kura Oncology, Inc. has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.